ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio is viewed as a differentiated, commercial-stage biotechnology company whose outlook is anchored by ANKTIVA’s expanding clinical and regulatory footprint, especially the FDA’s recent expansion into high-risk BCG-unresponsive NMIBC papillary-only disease, which may cover upwards of 60% of high-risk patients. The approval broadens the US addressable population beyond CIS +/- papillary disease, while prior efficacy data showed a 62% complete response rate and 58% of responders maintaining complete response for at least 12 months, supporting durability and commercial relevance. Beyond bladder cancer, randomized NSCLC and comparative bladder-sparing data reinforce ANKTIVA as an immune-restoration platform with additional upside from lung cancer, BCG-naïve trials, and early pipeline programs not yet fully reflected in the stock.

ImmunityBio is still exposed to substantial clinical, regulatory, and commercial uncertainty because ongoing and future trials may not prove sufficient efficacy for broader approvals, reimbursement, or adoption. The business also faces intense competitive pressure from approved and emerging therapies in similar patient populations, which can limit ANKTIVA’s commercial trajectory despite improved visibility in Europe. Financially, the company may need additional capital to fund commercialization, global expansion, and pipeline development, underscoring a risk profile that remains difficult for an early commercial-stage biotech.